RTP Mobile Logo
Investigator Perspectives on the Prevalence and Clinical Implications of Inaccurate or Misclassified Lymphoma Diagnoses in Community Oncology Practice
Released February 2018

Featuring interviews with Drs Mitchell R Smith, Fernando Cabanillas and Randy David Gascoyne on potential strategies to improve diagnostic accuracy in the field of lymphoma and chronic lymphocytic leukemia. (Audio Program)

CE Disclosures and Faculty Information

    The misclassification of lymphoma is a common clinical reality that can impede effective therapeutic decision-making and compromise outcomes for patients. A number of factors can lead to misdiagnosis in these cases. However, many may be mitigated through multidisciplinary collaboration and awareness. To this end, this CME activity encourages exchange between medical oncologists and hematopathologists, reviews available information and helps better define strategies to improve diagnostic accuracy.


    • Recognize common practical impediments (eg, inadequate sample size) to the accurate diagnostic assessment of lymphoid tissue, and use this information to improve internal and external processes and procedures.
    • Empower oncologists to more actively assess pathologic reporting to identify factors that could lead to misinterpretation.
    • Promote interdisciplinary collaboration between oncologists and pathologists to improve the accuracy of lymphoma subclassification.
    • Highlight the importance of immunohistochemistry (IHC) for lymphoma classification, and alert oncologists to the challenges associated with its interpretation.
    • Appreciate the specific IHC markers that should be included in a standard lymphoma panel, and discern how the selection and use of these markers differ in lymphoma subclassification.
    • Increase awareness of the incidence and relevance of CD30 overexpression in patients with T-cell lymphoma, Hodgkin lymphoma and diffuse large B-cell lymphoma, and develop strategies to appropriately determine CD30 positivity.
    • Formulate an evidence-based approach to biomarker analysis (cytogenetics, mutation status, et cetera) for patients with newly diagnosed and relapsed/refractory chronic lymphocytic leukemia, and appreciate the therapeutic implications of relevant findings.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    This CME activity contains an audio component. To receive credit, the participant should review the CME information, listen to the audio tracks, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located in the back of this booklet or on our website at ResearchToPractice.com/LymphomaMisclassification18/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/LymphomaMisclassification18/Video.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYDr Gascoyne has no relevant conflicts of interest to disclose. The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr SmithAdvisory Committee: Genentech BioOncology, Seattle Genetics; Contracted Research: Celgene Corporation, Takeda Oncology; Educational Presentation: AstraZeneca Pharmaceuticals LP. Dr CabanillasAdvisory Committee: Lilly, Merck, Pfizer Inc; Consulting Agreement: Bristol-Myers Squibb Company; Contracted Research: Abbott Laboratories, Celgene Corporation.

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc and Seattle Genetics.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: February 2018
    Expiration date: February 2019

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to audio:
Investigator Perspectives on the Prevalence and Clinical Implications of Inaccurate or Misclassified Lymphoma Diagnoses in Community Oncology Practice
Released February 2018

Featuring interviews with Drs Mitchell R Smith, Fernando Cabanillas and Randy David Gascoyne on potential strategies to improve diagnostic accuracy in the field of lymphoma and chronic lymphocytic leukemia. (Audio Program)

Read print: